New data reveals that seven children treated with Bluebird Bio’s gene therapy for a severe neurological disorder have developed blood cancer. This raises concerns about the safety of the therapy, particularly given the FDA’s approval of the treatment despite previous reports of cancer cases. Researchers are monitoring the patients closely and expect more cancer cases in the coming years.